Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society

Department of Surgery and Surgical Oncology, Charité Comprehensive Cancer Center, Charité-Universitätsmedizin Berlin, Berlin, Germany.
BMC Cancer (Impact Factor: 3.32). 03/2009; 9(1):50. DOI: 10.1186/1471-2407-9-50
Source: PubMed

ABSTRACT The additional use of radiotherapy has changed the treatment of locally advanced rectal cancer (LARC) dramatically. But a major achievement has been the development of total mesorectal excision (TME) as a surgical standard and the recognition that the surgeon is the predominant prognostic factor. The benefit of preoperative hypofractionated radiotherapy (SCRT; five fractions each of 5 Gy), initially established by the Swedish Rectal Cancer Trial, has been demonstrated in conjunction with TME by the Dutch Colorectal Cancer Group. The concept of combined neoadjuvant radiochemotherapy (conventional radiation of about 50 Gy with chemotherapy) has not been compared over surgery alone with TME. However, the German Rectal Cancer Study Group recently demonstrated that preoperative radiochemotherapy (RCT) was better than postoperative radiochemotherapy in terms of local control.
Patients with histological proven rectal cancer staged T2N+ or T3 are randomized to receive either SCRT (25 Gy in five fractions of 5 Gy) plus TME-surgery within 5 days or RCT (50.4 Gy in 28 fractions of 1.8 Gy, continuous infusion 5-fluorouracil) plus TME-surgery 4-6 weeks later. All patients receive adjuvant chemotherapy (12 weeks continuous infusional 5-FU) and are followed up for 5 years. TME-quality is independently documented by the surgeon and the pathologist. Hypothesis of the study is that RCT is superior to SCRT in terms of local recurrence after five years. Secondary endpoints are overall survival, disease-free survival, complete resection rate (R0 resection), rate of sphincter saving resection, acute and late toxicity (radiation related side effects), and quality of life (including long term bowel function).
Similar long-term survival, local control and late morbidity have been reported for both concepts of preoperative therapy in non-comparative studies. In addition to other ongoing (and recently published) comparative trials we include a larger number of patients for adequate power, apply quality-controlled TME and try to avoid the adjuvant treatment bias by mandatory adjuvant chemotherapy in both groups. Further more, stratification of the initially planned surgical procedure and sphincter-preservation will generate valid evidence whether RCT will allow a less aggressive (sphincter saving) surgical approach.

Download full-text


Available from: Stephan Koswig, Jun 25, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Evaluating impact of tumor regression grade in prognosis of patients with locally advanced rectal cancer (LARC). Materials and Methods. We identified from our colorectal cancer database 168 patients with LARC who received neoadjuvant therapy followed by complete mesorectum excision surgery between 2003 and 2011: 157 received 5-FU-based chemoradiation (CRT) and 11 short course RT. We excluded 29 patients, the remaining 139 were reassessed for disease recurrence and survival; the slides of surgical specimens were reviewed and classified according to Mandard tumor regression grades (TRG). We compared patients with good response (Mandard TRG1 or TRG2) versus patients with bad response (Mandard TRG3, TRG4, or TRG5). Outcomes evaluated were 5-year overall survival (OS), disease-free survival (DFS), local, distant and mixed recurrence. Results. Mean age was 64.2 years, and median followup was 56 months. No statistically significant survival difference was found when comparing patients with Mandard TRG1 versus Mandard TRG2 (p = .77). Mandard good responders (TRG1 + 2) have significantly better OS and DFS than Mandard bad responders (TRG3 + 4 + 5) (OS p = .013; DFS p = .007). Conclusions. Mandard good responders had a favorable prognosis. Tumor response (TRG) to neoadjuvant chemoradiation should be taken into account when defining the optimal adjuvant chemotherapy regimen for patients with LARC.
    01/2013; 2013:572149. DOI:10.1155/2013/572149
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of preoperative radiotherapy has resulted in significant downstaging and downsizing of tumor, this in turn facilitated resections permitting sphincter preservation and coloanal anastomosis for patients who would otherwise have not been candidates for this type of surgery as concluded by some small studies. On the other hand, other clinical trials have shown that the effect of radiotherapy on the rate of sphincter preservation is still not clear. Moreover, different modes of radiotherapy have been tested on the rate of sphincter preservation such as pelvic irradiation with or without combination of chemotherapy, short or conventional course radiotherapy, and preoperative or postoperative radiotherapy with different timing intervals of surgery. Unfortunately, these trials didn't clearly answer the question of radiotherapy benefit for the sake of sphincter preserving of rectal cancer patients and the question remained hotly debated.
    Surgical Oncology 04/2012; 21(3):e103-9. DOI:10.1016/j.suronc.2012.03.004 · 2.37 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment for high-risk colorectal cancer has evolved from surgical resection alone to the selective use of multimodalities such as chemotherapy and radiation therapy (RT). Postoperative RT can eradicate microscopic disease after surgical resection and preoperative RT leads to decreased tumor burden before the commencement of operation. The role of RT in the management of colon cancer is not confirmatory as of now. While there is some suspicion, no critical evidence can be found. However, some retrospective data support the role of RT to improve the prognosis in patients with colon cancer. Postoperative RT combined with chemotherapy can reduce the locoregional recurrences and exert a critical influence on patients' quality of life. Preoperative RT alone or the combination with chemotherapy down-stages the tumor to decrease the operative morbidity, and promotes the sphincter preservation. Preoperative RT improves local control. In addition, down-staging after neoadjuvant treatment merits attention as prognosticator. Patients who have had better tumor response also had superior survival profile. Treatment approach to locally advanced rectal cancer is changing from postoperative adjuvant one to aggressive application of preoperative modality. Future research efforts will focus the optimal treatment strategies to fortify the complete or near complete response rates. The recent advances in RT technology are also being examined to see whether the tumor response can be enhanced while decreasing toxicity so that more intensive chemotherapy regimens can be combined with RT. This review will trace the evolution of multimodality approach to locally advanced colorectal cancer.
    Journal of the Korean Medical Association 07/2010; 53(7):592. DOI:10.5124/jkma.2010.53.7.592 · 0.18 Impact Factor